Articles with tag: «cost-effectiveness analysis»
-
2022 № 4 Choosing optimal treatment organisation strategy for unresectable liver cancer: case of Moscow region
Introduction: despite quite low morbidity with up to 6 thousand cases per year in Russia, therapy for unresectable liver tumors is based on costly therapy with tyrosine kinase inhibitors or anti-PD‑1L agents thus leading to extremely high costs per life year saved. In the meantime, transaterial radioembolization (TARE)technique is reported to show better outcomes in this patient group compared to conservative treatment and transarterial chemotherapy (TACT). This article researches strategic options for regionwide treatment programs focused on involving TARE in unresectable liver tumors treatment.
Methodology. Epidemiological data provided by national cancer report. Systematic review of literature (not meeting PRISMA criteria) was done for TARE vs. TACT and TARE vs. conservative treatment overall survival. Treatment costs were based on current governmental treatment tariffs for Moscow region. Only direct oncology costs were included without possible complications analysis. The final analysis was done for optimistic, pessimistic and moderate expected numbers of patients eligble for TARE.
Results. Optimal treatment strategy implies maximum allowable rate of TARE with patients concentration in selected hospitals. For Moscow region (population of 7,6 million people) estimated yearly benefit of this strategy is 309,3 RUB (USD3,4 million USD) and 284 life years saved based on moderate prognosis. -
2013 № 9 Investment strategy to economic efficacy assessment of medical intervention (coronary artery bypass graft surgery) (Almazov Federal Heart, Blood and Endocrinology Centre, Saint-Petersburg State University of Service and Economics, Saint-Petersburg, Russia)
The studies of investment strategy as one of the methods of economic efficacy assessment of high-tech medical care (coronary artery bypass surgery, CABG), when medical care is considered to be an investment project (capital investment — is a high-tech medical care at the cost of R — into patient quality of life improvement) made possible future treatment cost reduction. The research has shown, that CABG is not only high clinical, but also cost effective economic medical intervention. Parameters of investment project efficacy were used to assess medical care cost-effectiveness. The result correlates with medical care value and patient life expectancy.
-
2021 № 4 COST-EFFECTIVENESS ANALYSIS OF MODERN MEDICAL TECHNOLOGIES MALDI-TOF MS FOR RAPID DIAGNOSTICS OF BACTERIAL INFECTIONS
The principle of rational antibiotic therapy can only be realized in the case of accurate and rapid identification of the pathogen. The spread of antibiotic resistance limits the choice of antimicrobial drugs and worsens the clinical prognosis for patients, so new strategies are needed to improve patient outcomes. The article presents a clinical and economic analysis of innovative technologies MALDI-TOF MS for the rapid diagnosis of microorganisms. Mass spectrometric identification of bacterial pathogens helps to reduce the time required for the issuance of the results of bacteriological analysis and an economically viable technology for use in routine practice of microbiological laboratories in Russia.